Atlanta Consulting Group Advisors’s Pfizer PFE Stock Holding History

Atlanta Consulting Group Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Buy	13,941 +232	+2%	+$6.07K	0.05%	145
2026 Q1	$385K	Sell	13,709 -78	-0.6%	-$2.08K	0.08%	102
2025 Q4	$343K	Buy	13,787 +970	+8%	+$24.5K	0.08%	115
2025 Q3	$327K	Hold	12,817	–	–	0.08%	104
2025 Q2	$311K	Sell	12,817 -204	-2%	-$4.76K	0.09%	102
2025 Q1	$330K	Sell	13,021 -49	-0.4%	-$1.28K	0.1%	88
2024 Q4	$347K	Sell	13,070 -33,716	-72%	-$915K	0.13%	90
2024 Q3	$1.35M	Buy	46,786 +34,293	+274%	+$1M	0.34%	55
2024 Q2	$350K	Buy	12,493 +1,060	+9%	+$29.2K	0.08%	86
2024 Q1	$317K	Buy	+11,433	New	+$317K	0.11%	97

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Atlanta Consulting Group Advisors's PFE Position: Q2 2026 in Review

Atlanta Consulting Group Advisors increased its Pfizer (PFE) stake by 1.7% in Q2 2026, buying an estimated $6.07K and bringing the position to 13,941 shares worth $336K. The position accounts for 0.05% of the portfolio, ranked #145.

Atlanta Consulting Group Advisors first reported a position in PFE in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.35M in Q3 2024. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Atlanta Consulting Group Advisors held 13,941 shares of Pfizer worth $336K as of Q2 2026.
Atlanta Consulting Group Advisors bought 232 Pfizer shares in Q2 2026, an estimated $6.07K.
Pfizer made up 0.05% of Atlanta Consulting Group Advisors's portfolio in Q2 2026, its #145 holding.
Atlanta Consulting Group Advisors first reported a position in Pfizer in Q1 2024 and has held it in 10 quarters since.
Atlanta Consulting Group Advisors's Pfizer position peaked at $1.35M in Q3 2024.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Atlanta Consulting Group Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.